Vertex Pharmaceuticals
Payors, Pharma Engage Alternative Payment Models Amid High Gene Therapy Cost, Efficacy Unknowns
Premium
Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.
Vertex Grabs Rights to Orum's Targeted Protein Degradation Technology
The deal, valued at more than $325 million, gives Vertex the right to use Orum's technology to develop new targeted conditioning agents for its gene therapies.
In Brief This Week: Solvias, Bristol Myers Squibb, Apollo Cancer Centers, FDA, Kyowa Kirin
News items for the week of Jan. 22, 2024.
In Brief This Week: Eisai, Biogen, Vertex, SpectronRx, Artbio, NorthStar Medical Radioisotopes
News items for the week of Jan.
JP Morgan Healthcare Conference Day 1: Bristol Myers Squibb, Vertex, Sarepta, Novartis, and More
On the first day, companies developing precision medicines and tests discussed plans for diversifying their portfolios and gaining regulatory approval for new products.